

# Isabelle Janoueix-Lerosey

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7388552/publications.pdf>

Version: 2024-02-01

78  
papers

7,592  
citations

87723

38  
h-index

66788

78  
g-index

82  
all docs

82  
docs citations

82  
times ranked

10509  
citing authors

#	ARTICLE	IF	CITATIONS
1	Control-FREEC: a tool for assessing copy number and allelic content using next-generation sequencing data. <i>Bioinformatics</i> , 2012, 28, 423-425.	1.8	847
2	Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma. <i>Nature</i> , 2008, 455, 967-970.	13.7	787
3	Interaction of a Golgi-Associated Kinesin-Like Protein with Rab6. <i>Science</i> , 1998, 279, 580-585.	6.0	478
4	Relapsed neuroblastomas show frequent RAS-MAPK pathway mutations. <i>Nature Genetics</i> , 2015, 47, 864-871.	9.4	451
5	Heterogeneity of neuroblastoma cell identity defined by transcriptional circuitries. <i>Nature Genetics</i> , 2017, 49, 1408-1413.	9.4	331
6	Germline Mutations of the Paired- <i>Like</i> Homeobox 2B (PHOX2B) Gene in Neuroblastoma. <i>American Journal of Human Genetics</i> , 2004, 74, 761-764.	2.6	288
7	Overall Genomic Pattern Is a Predictor of Outcome in Neuroblastoma. <i>Journal of Clinical Oncology</i> , 2009, 27, 1026-1033.	0.8	288
8	Control-free calling of copy number alterations in deep-sequencing data using GC-content normalization. <i>Bioinformatics</i> , 2011, 27, 268-269.	1.8	249
9	Meta-analysis of Neuroblastomas Reveals a Skewed <i>ALK</i> Mutation Spectrum in Tumors with <i>MYCN</i> Amplification. <i>Clinical Cancer Research</i> , 2010, 16, 4353-4362.	3.2	243
10	SVDetect: a tool to identify genomic structural variations from paired-end and mate-pair sequencing data. <i>Bioinformatics</i> , 2010, 26, 1895-1896.	1.8	178
11	Predicting outcomes for children with neuroblastoma using a multigene-expression signature: a retrospective SIOPEN/COG/GPOH study. <i>Lancet Oncology</i> , The, 2009, 10, 663-671.	5.1	176
12	Emergence of New <i>ALK</i> Mutations at Relapse of Neuroblastoma. <i>Journal of Clinical Oncology</i> , 2014, 32, 2727-2734.	0.8	176
13	Beta-catenin status in paediatric medulloblastomas: correlation of immunohistochemical expression with mutational status, genetic profiles, and clinical characteristics. <i>Journal of Pathology</i> , 2009, 218, 86-94.	2.1	171
14	Characterization of Novel Rab6-Interacting Proteins Involved in Endosome-to-TGN Transport. <i>Traffic</i> , 2002, 3, 289-297.	1.3	145
15	Accumulation of Segmental Alterations Determines Progression in Neuroblastoma. <i>Journal of Clinical Oncology</i> , 2010, 28, 3122-3130.	0.8	142
16	Prognostic Impact of Gene Expression-Based Classification for Neuroblastoma. <i>Journal of Clinical Oncology</i> , 2010, 28, 3506-3515.	0.8	129
17	Whole-Exome Sequencing of Cell-Free DNA Reveals Temporo-spatial Heterogeneity and Identifies Treatment-Resistant Clones in Neuroblastoma. <i>Clinical Cancer Research</i> , 2018, 24, 939-949.	3.2	127
18	VAMP: Visualization and analysis of array-CGH, transcriptome and other molecular profiles. <i>Bioinformatics</i> , 2006, 22, 2066-2073.	1.8	106

#	ARTICLE	IF	CITATIONS
19	Two-hybrid System Screen with the Small GTP-binding Protein Rab6. IDENTIFICATION OF A NOVEL MOUSE GDP DISSOCIATION INHIBITOR ISOFORM AND TWO OTHER POTENTIAL PARTNERS OF Rab6. <i>Journal of Biological Chemistry</i> , 1995, 270, 14801-14808.	1.6	104
20	Transcriptional Programs Define Intratumoral Heterogeneity of Ewing Sarcoma at Single-Cell Resolution. <i>Cell Reports</i> , 2020, 30, 1767-1779.e6.	2.9	96
21	The occurrence of intracranial rhabdoid tumours in mice depends on temporal control of Smarcb1 inactivation. <i>Nature Communications</i> , 2016, 7, 10421.	5.8	92
22	Recent insights into the biology of neuroblastoma. <i>International Journal of Cancer</i> , 2014, 135, 2249-2261.	2.3	91
23	Activated Alk triggers prolonged neurogenesis and Ret upregulation providing a therapeutic target in ALK-mutated neuroblastoma. <i>Oncotarget</i> , 2014, 5, 2688-2702.	0.8	89
24	Accurate Outcome Prediction in Neuroblastoma across Independent Data Sets Using a Multigene Signature. <i>Clinical Cancer Research</i> , 2010, 16, 1532-1541.	3.2	86
25	Molecular pathogenesis of peripheral neuroblastic tumors. <i>Oncogene</i> , 2010, 29, 1566-1579.	2.6	84
26	Revised Risk Estimation and Treatment Stratification of Low- and Intermediate-Risk Neuroblastoma Patients by Integrating Clinical and Molecular Prognostic Markers. <i>Clinical Cancer Research</i> , 2015, 21, 1904-1915.	3.2	80
27	Upregulation of MAPK Negative Feedback Regulators and RET in Mutant ALK Neuroblastoma: Implications for Targeted Treatment. <i>Clinical Cancer Research</i> , 2015, 21, 3327-3339.	3.2	76
28	Midkine and Alk signaling in sympathetic neuron proliferation and neuroblastoma predisposition. <i>Development (Cambridge)</i> , 2011, 138, 4699-4708.	1.2	72
29	Identification and Characterization of Potential Effector Molecules of the Ras-related GTPase Rap2. <i>Journal of Biological Chemistry</i> , 1999, 274, 8737-8745.	1.6	70
30	Germline mutations of the paired-like homeobox 2B (PHOX2B) gene in neuroblastoma. <i>Cancer Letters</i> , 2005, 228, 51-58.	3.2	63
31	Deep Sequencing Reveals Occurrence of Subclonal <i>ALK</i> Mutations in Neuroblastoma at Diagnosis. <i>Clinical Cancer Research</i> , 2015, 21, 4913-4921.	3.2	62
32	Identification of a specific effector of the small GTP-binding protein Rap2. <i>FEBS Journal</i> , 1998, 252, 290-298.	0.2	60
33	Gene expression profiling of 1p35-36 genes in neuroblastoma. <i>Oncogene</i> , 2004, 23, 5912-5922.	2.6	60
34	Characterization of Rearrangements Involving the <i>ALK</i> Gene Reveals a Novel Truncated Form Associated with Tumor Aggressiveness in Neuroblastoma. <i>Cancer Research</i> , 2013, 73, 195-204.	0.4	54
35	Combined 24-color karyotyping and comparative genomic hybridization analysis indicates predominant rearrangements of early replicating chromosome regions in neuroblastoma. <i>Cancer Genetics and Cytogenetics</i> , 2003, 141, 32-42.	1.0	53
36	Repurposing rotavirus vaccines for intratumoral immunotherapy can overcome resistance to immune checkpoint blockade. <i>Science Translational Medicine</i> , 2019, 11, .	5.8	49

#	ARTICLE	IF	CITATIONS
37	Activated ALK signals through the ERK-ETV5-RET pathway to drive neuroblastoma oncogenesis. <i>Oncogene</i> , 2018, 37, 1417-1429.	2.6	45
38	Breakpoint Features of Genomic Rearrangements in Neuroblastoma with Unbalanced Translocations and Chromothripsis. <i>PLoS ONE</i> , 2013, 8, e72182.	1.1	42
39	Radiogenomics of neuroblastomas: Relationships between imaging phenotypes, tumor genomic profile and survival. <i>PLoS ONE</i> , 2017, 12, e0185190.	1.1	40
40	Characterization of amplicons in neuroblastoma: High-resolution mapping using DNA microarrays, relationship with outcome, and identification of overexpressed genes. <i>Genes Chromosomes and Cancer</i> , 2008, 47, 819-834.	1.5	39
41	Germline gain-of-function mutations of ALK disrupt central nervous system development. <i>Human Mutation</i> , 2011, 32, 272-276.	1.1	38
42	ALK germline mutations in patients with neuroblastoma: a rare and weakly penetrant syndrome. <i>European Journal of Human Genetics</i> , 2012, 20, 291-297.	1.4	38
43	Stepwise occurrence of a complex unbalanced translocation in neuroblastoma leading to insertion of a telomere sequence and late chromosome 17q gain. <i>Oncogene</i> , 2005, 24, 3377-3384.	2.6	36
44	SV-Bay: structural variant detection in cancer genomes using a Bayesian approach with correction for GC-content and read mappability. <i>Bioinformatics</i> , 2016, 32, 984-992.	1.8	36
45	Variety and complexity of chromosome 17 translocations in neuroblastoma. <i>Genes Chromosomes and Cancer</i> , 2004, 39, 143-150.	1.5	35
46	Unraveling Ewing Sarcoma Tumorigenesis Originating from Patient-Derived Mesenchymal Stem Cells. <i>Cancer Research</i> , 2021, 81, 4994-5006.	0.4	35
47	Preferential Occurrence of Chromosome Breakpoints within Early Replicating Regions in Neuroblastoma. <i>Cell Cycle</i> , 2005, 4, 1842-1846.	1.3	33
48	Learning smoothing models of copy number profiles using breakpoint annotations. <i>BMC Bioinformatics</i> , 2013, 14, 164.	1.2	33
49	Lin28B and Let-7 in the Control of Sympathetic Neurogenesis and Neuroblastoma Development. <i>Journal of Neuroscience</i> , 2015, 35, 16531-16544.	1.7	32
50	Wild-type ALK and activating ALK-R1275Q and ALK-F1174L mutations upregulate Myc and initiate tumor formation in murine neural crest progenitor cells. <i>Oncotarget</i> , 2014, 5, 4452-4466.	0.8	32
51	RGS14 is a novel Rap effector that preferentially regulates the GTPase activity of G12o. <i>Biochemical Journal</i> , 2000, 350, 19.	1.7	31
52	The ALK receptor in sympathetic neuron development and neuroblastoma. <i>Cell and Tissue Research</i> , 2018, 372, 325-337.	1.5	31
53	Plasticity in Neuroblastoma Cell Identity Defines a Noradrenergic-to-Mesenchymal Transition (NMT). <i>Cancers</i> , 2021, 13, 2904.	1.7	29
54	Regulation by miR181 Family of the Dependence Receptor CDON Tumor Suppressive Activity in Neuroblastoma. <i>Journal of the National Cancer Institute</i> , 2014, 106, .	3.0	27

#	ARTICLE	IF	CITATIONS
55	Internalization and Down-Regulation of the ALK Receptor in Neuroblastoma Cell Lines upon Monoclonal Antibodies Treatment. <i>PLoS ONE</i> , 2012, 7, e33581.	1.1	27
56	Molecular analysis of chromosome arm 17q gain in neuroblastoma. <i>Genes Chromosomes and Cancer</i> , 2000, 28, 276-284.	1.5	26
57	Cholinergic switch associated with morphological differentiation in neuroblastoma. <i>Journal of Pathology</i> , 2009, 219, 463-472.	2.1	26
58	Methylation-associated PHOX2B gene silencing is a rare event in human neuroblastoma. <i>European Journal of Cancer</i> , 2007, 43, 2366-2372.	1.3	20
59	QuantumClone: clonal assessment of functional mutations in cancer based on a genotype-aware method for clonal reconstruction. <i>Bioinformatics</i> , 2018, 34, 1808-1816.	1.8	20
60	Regulation of the GTPase activity of the ras-related rap2 protein. <i>Biochemical and Biophysical Research Communications</i> , 1992, 189, 455-464.	1.0	18
61	Clinical Characteristics and Outcome of Patients with Neuroblastoma Presenting Genomic Amplification of Loci Other than MYCN. <i>PLoS ONE</i> , 2014, 9, e101990.	1.1	17
62	Study of chromatin remodeling genes implicates SMARCA4 as a putative player in oncogenesis in neuroblastoma. <i>International Journal of Cancer</i> , 2019, 145, 2781-2791.	2.3	16
63	Targeting netrin-3 in small cell lung cancer and neuroblastoma. <i>EMBO Molecular Medicine</i> , 2021, 13, e12878.	3.3	16
64	Integrative analysis identifies lincRNAs up- and downstream of neuroblastoma driver genes. <i>Scientific Reports</i> , 2019, 9, 5685.	1.6	14
65	High-resolution mapping of amplicons of the short arm of chromosome 1 in two neuroblastoma tumors by microarray-based comparative genomic hybridization. <i>Genes Chromosomes and Cancer</i> , 2004, 40, 266-270.	1.5	13
66	Segmental Chromosomal Aberrations in Localized Neuroblastoma Can be Detected in Formalin-Fixed Paraffin-Embedded Tissue Samples and Are Associated With Recurrence. <i>Pediatric Blood and Cancer</i> , 2016, 63, 1019-1023.	0.8	13
67	The sympathetic nervous system: malignancy, disease, and novel functions. <i>Cell and Tissue Research</i> , 2018, 372, 163-170.	1.5	12
68	SegAnnDB: interactive Web-based genomic segmentation. <i>Bioinformatics</i> , 2014, 30, 1539-1546.	1.8	10
69	<sup>68</sup> Ga-DOTATOC and FDG PET Imaging of Preclinical Neuroblastoma Models. <i>Anticancer Research</i> , 2016, 36, 4459-4466.	0.5	10
70	HMCAn-diff: a method to detect changes in histone modifications in cells with different genetic characteristics. <i>Nucleic Acids Research</i> , 2017, 45, gkw1319.	6.5	8
71	Use of the Two-Hybrid System to Identify Rab-Interacting Proteins. <i>Methods</i> , 2000, 20, 399-402.	1.9	7
72	Hyperactivation of Alk induces neonatal lethality in knock-in AlkF1178L mice. <i>Oncotarget</i> , 2014, 5, 2703-2713.	0.8	6

#	ARTICLE	IF	CITATIONS
73	ALK mutation dynamics and clonal evolution in a neuroblastoma model exhibiting two ALK mutations. <i>Oncotarget</i> , 2019, 10, 4937-4950.	0.8	5
74	Two cases of localized neuroblastoma with multiple segmental chromosomal alterations and metastatic progression. <i>Pediatric Blood and Cancer</i> , 2013, 60, 332-335.	0.8	3
75	Midkine and Alk signaling in sympathetic neuron proliferation and neuroblastoma predisposition. <i>Journal of Cell Science</i> , 2011, 124, e1-e1.	1.2	1
76	BET and CDK Inhibition Reveal Differences in the Proliferation Control of Sympathetic Ganglion Neuroblasts and Adrenal Chromaffin Cells. <i>Cancers</i> , 2022, 14, 2755.	1.7	1
77	High CD44 expression is not a prognosis marker in patients with high-risk neuroblastoma. <i>EBioMedicine</i> , 2020, 53, 102702.	2.7	0
78	Neuroblastoma Pathogenesis. , 2020, , 29-56.		0